Get the Stockscreener App
7.7347
0.96%
-0.0753
Cervomed Inc stock is traded at $7.7347, with a volume of 3,703.
It is down -0.96% in the last 24 hours and down -10.99% over the past month.
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$7.81
Open:
$7.84
24h Volume:
3,703
Relative Volume:
0.05
Market Cap:
$72.63M
Revenue:
-
Net Income/Loss:
$-6.42M
P/E Ratio:
-1.3809
EPS:
-5.6013
Net Cash Flow:
$-7.45M
1W Performance:
-3.07%
1M Performance:
-10.99%
6M Performance:
+36.90%
1Y Performance:
+230.55%
1-Day Range:
$7.73
$7.85
1-Week Range:
$7.43
$8.025
52-Week Range:
$1.92
$16.94
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
7.85 | 72.26M | 0 | -6.42M | -7.45M | -5.6013 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.91 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
780.61 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.65 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.52 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.23 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
Is CervoMed Inc DP8 a good long term investmentMarket Sentiment Report & Learn From the Strategies of Institutions - earlytimes.in
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
CervoMed Inc. (NASDAQ:CRVO) Given Average Rating of “Moderate Buy” by Brokerages - Defense World
Will CervoMed Inc. stock see insider buyingVolume Analysis Techniques & Small Entry Cost Portfolio - bollywoodhelpline.com
Can CervoMed Inc. stock rebound after recent weakness2025 Market Overview & Risk Controlled Swing Alerts - Улправда
Will CervoMed Inc. (DP8) stock return to pre crash levels2025 Trading Volume Trends & Technical Pattern Based Signals - Улправда
What analyst consensus says on CervoMed Inc. stockStock Surge & Verified High Yield Trade Plans - Улправда
Is CervoMed Inc. stock vulnerable to regulatory risksEarnings Miss & Technical Analysis for Trade Confirmation - DonanımHaber
Aug Patterns: Will CervoMed Inc. stock gain from strong economyProduct Launch & AI Based Buy and Sell Signals - DonanımHaber
Why CervoMed Inc. (DP8) stock attracts wealthy investorsStop Loss & Advanced Technical Signal Analysis - DonanımHaber
Will CervoMed Inc. stock gain from strong economyWeekly Trend Recap & Daily Volume Surge Signals - Bölüm Sonu Canavarı
CervoMed (NASDAQ:CRVO) Receives Buy Rating from HC Wainwright - Defense World
Can CervoMed Inc. stock sustain institutional interest2025 Pullback Review & High Yield Equity Trading Tips - Улправда
Cantor Fitzgerald initiates CervoMed stock with Overweight rating By Investing.com - Investing.com South Africa
Cantor Fitzgerald Initiates Coverage on CervoMed (CRVO) with Ove - GuruFocus
HC Wainwright Reaffirms Buy Rating for CervoMed (NASDAQ:CRVO) - MarketBeat
Cantor Fitzgerald Initiates Coverage on CervoMed With Overweight Rating - marketscreener.com
Cantor Fitzgerald initiates CervoMed stock with Overweight rating - Investing.com India
CervoMed Earnings Notes - Trefis
CEO Change: Is CervoMed Inc DP8 stock supported by strong fundamentals2025 Trading Volume Trends & Technical Pattern Based Signals - moha.gov.vn
New Highs: Can CervoMed Inc. stock rebound after recent weaknessJuly 2025 Gainers & Precise Swing Trade Entry Alerts - moha.gov.vn
Pleasing Signs As A Number Of Insiders Buy CervoMed Stock - Yahoo Finance
CervoMed Inc. (NASDAQ:CRVO) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Published on: 2025-12-06 11:12:10 - moha.gov.vn
CervoMed Inc Announces New Data from RewinD-LB Trial - TradingView — Track All Markets
Today's Analyst Rating: CRVO Maintains "Buy" with $31 Price Targ - GuruFocus
Will CervoMed Inc. (DP8) stock benefit from Fed rate cutsJuly 2025 Intraday Action & Daily Volume Surge Signals - Newser
What RSI levels show for CervoMed Inc. (DP8) stockPortfolio Gains Report & Technical Confirmation Trade Alerts - Newser
CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies - The Manila Times
Why CervoMed Inc. (DP8) stock is a strong analyst pickEarnings Performance Report & Risk Managed Trade Strategies - Newser
Cervomed (CRVO) Unveils Promising Phase 2b Trial Results for Nef - GuruFocus
CervoMed’s DLB drug shows promise in phase 2b trial By Investing.com - Investing.com Nigeria
CervoMed’s DLB drug shows promise in phase 2b trial - Investing.com
CervoMed stock soars after promising dementia drug trial results By Investing.com - Investing.com South Africa
CervoMed stock soars after promising dementia drug trial results - Investing.com
CervoMed Inc. Reports Phase 2b RewinD-LB Trial Results for Neflamapimod, Showing Significant Improvements in Dementia with Lewy Bodies Patients - Quiver Quantitative
CervoMed Announces Late-Breaking Data at the 18th CTAD - GlobeNewswire
How rising interest rates impact CervoMed Inc. stockPortfolio Value Report & Safe Swing Trade Setups - Newser
Is CervoMed Inc. stock attractive after correctionJuly 2025 Action & Fast Exit and Entry Strategy Plans - Newser
Why CervoMed Inc. (DP8) stock stays undervaluedM&A Rumor & Short-Term High Return Strategies - Newser
CervoMed's (CRVO) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat
Neflamapimod reduces key neurodegeneration markers in DLB study By Investing.com - Investing.com Canada
CervoMed (NASDAQ:CRVO) Receives Buy Rating from D. Boral Capital - Defense World
CervoMed (CRVO) Maintains Buy Rating with Target Price of $31 | - GuruFocus
CervoMed (CRVO) Unveils Promising Phase 2b Trial Results for Alz - GuruFocus
Neflamapimod reduces key neurodegeneration markers in DLB study - Investing.com
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.60%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):